Synthesis of Recommendations From 25 Countries and 31 Oncology Societies: How to Navigate Through Covid-19 Labyrinth.
Covid-19
international
oncology
recommendations
societies
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
06
2020
accepted:
16
10
2020
entrez:
17
12
2020
pubmed:
18
12
2020
medline:
18
12
2020
Statut:
epublish
Résumé
Pandemic COVID-19 is an unexpected challenge for the oncological community, indicating potential detrimental effects on cancer patients. Our aim was to summarize the converging key points providing a general guidance in order to support decision making, pertaining to the oncologic care in the middle of a global outbreak. We did an international online search in twenty five countries that have managed a surge in cancer patient numbers. We collected the recommendations from thirty one medical oncology societies. By synthesizing guidelines for a) oncology service delivery adjustments, b) general and specific treatment adaptations, and c) discrepancies from guidelines comparison, we present a clinical synopsis with the forty more crucial statements. A Covid-19 risk stratification base was also created in order to obtain a quick, objective patient assessment and a risk-benefit evaluation on a case-by-case basis. In an attempt to face these complex needs and due to limited understanding of COVID-19, a variability of recommendations based on general epidemiological and infectious disease principles rather than definite cancer-related evidence has evolved. Additionally, the absence of an effective treatment or vaccine requires the development of cancer management guidance, capitalizing on comprehensive COVID-19 oncology experience globally.
Identifiants
pubmed: 33330049
doi: 10.3389/fonc.2020.575148
pmc: PMC7711151
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
575148Informations de copyright
Copyright © 2020 Kamposioras, Mauri, Papadimitriou, Anthoney, Hindi, Petricevic, Dambrosio, Valachis, Kountourakis, Kopecky, Kuhar, Popovic, Chilingirova, Zarkavelis, de Mello, Plavetić, Christopoulos, Mostert, Goffin, Tzachanis, Saraireh, Ma, Pavese and Tolia.
Références
JAMA. 2020 Apr 14;323(14):1406-1407
pubmed: 32083643
J Transl Med. 2020 May 20;18(1):206
pubmed: 32434518
Int J Infect Dis. 2010 Dec;14(12):e1099-105
pubmed: 21036090
N Engl J Med. 2020 Jun 11;382(24):2285-2287
pubmed: 32267650
N Engl J Med. 2020 Mar 19;382(12):1177-1179
pubmed: 32074444
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32302401
J Natl Compr Canc Netw. 2020 Mar 20;:1-4
pubmed: 32197238
Ann Oncol. 2020 Jul;31(7):894-901
pubmed: 32224151
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Immunotherapy. 2020 Apr;12(6):351-354
pubmed: 32290754
Lancet Oncol. 2020 Jun;21(6):759-760
pubmed: 32410877
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Emerg Infect Dis. 2004 May;10(5):782-8
pubmed: 15200809
Ann Oncol. 2020 Jul;31(7):951-957
pubmed: 32325257
Ann Oncol. 2020 Oct;31(10):1320-1335
pubmed: 32745693
Influenza Other Respir Viruses. 2013 Nov;7(6):1328-35
pubmed: 23551904
Ann Oncol. 2020 May;31(5):553-555
pubmed: 32201224
Lancet Oncol. 2020 May;21(5):619-621
pubmed: 32220659
JAMA Oncol. 2020 May 1;6(5):631-632
pubmed: 32236504
Immunotherapy. 2020 Apr;12(5):269-273
pubmed: 32212881
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
JAMA Oncol. 2019 Jul 1;5(7):1008-1019
pubmed: 31021376
Arterioscler Thromb Vasc Biol. 2019 Sep;39(9):1724-1738
pubmed: 31315434
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578